ERBB2 and gastroesophageal junction adenocarcinoma: In this retrospective study, we provided the initial picture of the comparison on different treatment patterns as trastuzumab plus chemotherapy with or without anti-PD-1-based immunotherapy in HER2 positive GC/GEJ adenocarcinoma from one single center.